West Pharmaceutical Services - WST Stock Forecast, Price & News

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for West Pharmaceutical Services in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" WST shares.
View WST analyst ratings or view top-rated stocks.

4 brokerages have issued 12 month price objectives for West Pharmaceutical Services' stock. Their WST share price forecasts range from $250.00 to $350.00. On average, they predict the company's share price to reach $283.33 in the next year. This suggests a possible upside of 20.7% from the stock's current price.
View analysts price targets for WST or view top-rated stocks among Wall Street analysts.

West Pharmaceutical Services' stock was trading at $469.01 at the start of the year. Since then, WST shares have decreased by 50.0% and is now trading at $234.66.
View the best growth stocks for 2022 here.

West Pharmaceutical Services saw a increase in short interest in November. As of November 15th, there was short interest totaling 993,800 shares, an increase of 18.1% from the October 31st total of 841,400 shares. Based on an average daily trading volume, of 680,900 shares, the days-to-cover ratio is currently 1.5 days. Approximately 1.4% of the shares of the company are sold short.
View West Pharmaceutical Services' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 16th 2023.
View our WST earnings forecast.

West Pharmaceutical Services, Inc. (NYSE:WST) announced its quarterly earnings results on Thursday, October, 27th. The medical instruments supplier reported $2.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.12 by $0.09. The medical instruments supplier earned $686.90 million during the quarter, compared to analyst estimates of $730.64 million. West Pharmaceutical Services had a net margin of 21.68% and a trailing twelve-month return on equity of 28.15%.

West Pharmaceutical Services declared a quarterly dividend on Thursday, October 27th. Stockholders of record on Wednesday, November 9th will be given a dividend of $0.19 per share on Wednesday, November 16th. This represents a $0.76 annualized dividend and a dividend yield of 0.32%. The ex-dividend date is Tuesday, November 8th. This is a boost from the stock's previous quarterly dividend of $0.18.
Read our dividend analysis for WST.

West Pharmaceutical Services (NYSE:WST) pays an annual dividend of $0.76 per share and currently has a dividend yield of 0.34%. The company has been increasing its dividend for 29 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 9.17%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, WST will have a dividend payout ratio of 10.16% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for WST.

West Pharmaceutical Services updated its FY 2022 earnings guidance on Thursday, November, 3rd. The company provided earnings per share (EPS) guidance of $8.15-$8.20 for the period, compared to the consensus estimate of $9.07. The company issued revenue guidance of $2.83 billion-$2.84 billion, compared to the consensus revenue estimate of $2.98 billion.

107 employees have rated West Pharmaceutical Services Chief Executive Officer Eric M. Green on Glassdoor.com. Eric M. Green has an approval rating of 75% among the company's employees. 60.0% of employees surveyed would recommend working at West Pharmaceutical Services to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other West Pharmaceutical Services investors own include NVIDIA (NVDA), Johnson & Johnson (JNJ), AbbVie (ABBV), Walt Disney (DIS), Home Depot (HD), Visa (V), Alibaba Group (BABA), McDonald's (MCD), Netflix (NFLX) and PepsiCo (PEP).

West Pharmaceutical Services trades on the New York Stock Exchange (NYSE) under the ticker symbol "WST."

West Pharmaceutical Services' stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (12.06%), BlackRock Inc. (10.93%), Price T Rowe Associates Inc. MD (5.23%), State Street Corp (4.50%), Bank of New York Mellon Corp (2.35%) and WCM Investment Management LLC (1.67%). Insiders that own company stock include Annette F Favorite, David A Montecalvo, George Lloyd Miller, Patrick J Zenner, Quintin J Lai and Silji Abraham.
View institutional ownership trends.

Shares of WST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of WST stock can currently be purchased for approximately $234.66.

West Pharmaceutical Services (NYSE:WST) has a market capitalization of $17.37 billion and generates $2.83 billion in revenue each year. The medical instruments supplier earns $661.80 million in net income (profit) each year or $8.29 on an earnings per share basis.

The company employs 10,065 workers across the globe.

West Pharmaceutical Services' mailing address is 530 HERMAN O. WEST DRIVE, EXTON PA, 19341. The official website for the company is www.westpharma.com. The medical instruments supplier can be reached via phone at (610) 594-2900, via email at quintin.lai@westpharma.com, or via fax at 800-345-9800.